Mohammad Murshid Alam

Immunology and Microbiology · Life Sciences

23h-index1.2kcitations94works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(40), CAR-T cell therapy research(32), Immunotherapy and Immune Responses(29), Vibrio bacteria research studies(20), Escherichia coli research studies(15)

Publications94 total

Figure S1 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S8 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S10 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S4 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S3 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S5 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S2 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S9 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S7 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Figure S6 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2025Open Access
Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis
SKIN The Journal of Cutaneous Medicine·2025· 1 citedOpen Access
Preclinical and Pharmacokinetic Characterization of APG333: A Fully Human Monoclonal Antibody that Binds TSLP with High Affinity and Potently Inhibits Downstream Signaling
Journal of Allergy and Clinical Immunology·2025
Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity
ACS Nano·2024· 14 citedOpen Access
CH−π Interactions Are Required for Human Galectin-3 Function
JACS Au·2024· 10 citedOpen Access
Glycan-costumed virus-like particles promote type 1 anti-tumor immunity
2024Open Access
Figure S1 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2023Open Access
Figure S8 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2023Open Access
Figure S5 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2023Open Access
Figure S9 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2023Open Access
Figure S10 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Edward T. Ryan(20), Stephen B. Calderwood(18), Ben Umiker(16), Yasmin Hashambhoy-Ramsay(16), Tanzila Rahman(16), Amy Mueller(16), Rachel Davidson(16), Christina Meyer(16), Gayatri Patankar(16), Sarah Jaffe(16), Kristin Krukenberg(16), Allison Goodman(16), Vikki Spaulding(16), Michelle Priess(16), Abha Dhaneshwar(16), Masie Wong(16), Alexa Diiorio(16), Kristin O'Malley(16), Lara McGrath(16), Margaret Willer(16)